方盛制药：控股子公司获得《药品生产许可证》

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., has received a Drug Production License from the Guangdong Provincial Drug Administration, allowing it to act as the marketing authorization holder for the drug Riluzole Tablets, with Fangsheng Pharmaceutical as the entrusted party [1] Group 1 - The approval of the Drug Production License signifies a key regulatory milestone for Fangsheng Ronghua, enhancing its operational capabilities in the pharmaceutical market [1] - Riluzole Tablets are indicated for the treatment of amyotrophic lateral sclerosis (ALS), which may expand the company's product portfolio and market reach [1] - The collaboration between Fangsheng Ronghua and Fangsheng Pharmaceutical indicates a strategic partnership aimed at leveraging each other's strengths in drug development and commercialization [1]